At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 72 enrolled
Drug / intervention
open-label selective serotonin reuptake inhibitor (SSRI)drug
Likely dose
open-label selective serotonin reuptake inhibitor (SSRI) 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Serum Brain-Derived Neurotrophic Factor (BDNF) and QEEG as Biological Markers of Response to (Es)Citalopram Treatment in Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating open-label selective serotonin reuptake inhibitor (SSRI) for Major Depressive Disorder. Completed, enrolled 72 participants.
Detailed Summary
The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or escitalopram).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedAug 2006
Primary CompletionDec 2008
TodayJul 2026
First PostedAug 8, 2006
Enrollment StartOct 1, 2005
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 19.9 years ago
Interventions
open-label selective serotonin reuptake inhibitor (SSRI)drug
Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.